Clin2
NCT07534007Likely a fitRecruiting

Shingles vaccine response in patients on immune-modifying drugs

RZV Vaccine (Shingrix ®)

Part of Immune system & allergy, Infections clinical trials.

This study tests a new shingles vaccine in people with psoriasis or myelofibrosis, some of whom take immune-modifying medications. Researchers want to understand how well the vaccine works and how the immune system responds in these groups.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
150 people
Ages
18 years to 100 years
Study type
Observational

Who can take part

  • You are 18 years old or older
  • You have either psoriasis or myelofibrosis (a blood marrow condition)
  • You are expected to live at least 12 more months
  • You are willing to sign an informed consent form
  • You have not previously enrolled in this specific study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07321808Recruiting
Shingles vaccine study for frail patients

This study tests how well the shingles vaccine works in people with weakened immune systems due to conditions like rheumatoid arthritis, cancer, or multiple sclerosis. It aims to see if the vaccine is safe and effective for these patients.

Pavia, Pavia
NCT06364033Not yet recruiting
Shingrix vaccine for people with CLL

This study tests whether the Shingrix vaccine prevents shingles in people with CLL (a type of blood cancer). It will look at how well the vaccine works and helps your immune system fight the virus.

Varese
NCT07047053Recruiting
Shingles vaccine study for people with autoimmune diseases

This study looks at how well the shingles vaccine works in people with autoimmune inflammatory diseases. Researchers want to make sure the vaccine provides good protection for patients whose immune systems are affected by their condition or treatment.

Paris
NCT04748939Not yet recruiting· Phase 4
Shingrix vaccine study for people with rheumatic immune diseases

This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.

Hong Kong
NCT06763783Enrolling by invitation· Phase 4
Shingles vaccine study for people with rheumatic diseases

This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.

Lund
NCT07636044Recruiting
Shingles Vaccine Response in Lupus Patients

This study tests how well the shingles vaccine (Shingrix) works in people with lupus who take immune-suppressing medications. Researchers want to understand if the vaccine provides good protection in lupus patients, since their immune systems work differently.

Seoul

Hear when a new RZV Vaccine (Shingrix ®) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.